Medicine and Dentistry
Radiation Therapy
100%
Breast Cancer
89%
Neoplasm
74%
Malignant Neoplasm
63%
Chemotherapy
54%
Overall Survival
52%
Head and Neck Cancer
36%
Disease
35%
Cohort Analysis
30%
Melanoma
29%
Quality of Life
28%
Recurrent Disease
27%
Non Small Cell Lung Cancer
27%
Metastatic Colorectal Cancer
24%
Metastatic Carcinoma
22%
Magnetic Resonance Imaging
20%
Positron Emission Tomography-Computed Tomography
20%
Hazard Ratio
17%
Oncology
17%
Progression Free Survival
17%
Clinical Trial
16%
Prognostic Factor
16%
Pancreas Cancer
16%
Biological Marker
15%
Adverse Event
14%
Immunotherapy
14%
Lung
13%
Comorbidity
13%
Surgery
13%
Colorectal Carcinoma
13%
Neck
13%
Randomized Controlled Trial
13%
Cancer Therapy
13%
Primary Tumor
13%
Diagnosis
13%
Ganglioglioma
12%
Lung Cancer
12%
Head and Neck Squamous Cell Carcinoma
12%
Arm
12%
Squamous Cell Carcinoma
12%
Systematic Review
12%
Glioblastoma
11%
Treatment Planning
11%
Symptomatic Treatment
11%
Chemoradiotherapy
11%
Stereotactic Body Radiation Therapy
11%
Cancer Cell
10%
Estrogen Receptor
10%
Systemic Therapy
10%
Metastatic Melanoma
10%
Prostate Cancer
10%
Patient-Reported Outcome
10%
Oxaliplatin
10%
Adjuvant Therapy
9%
Biopsy Technique
9%
Testis Cancer
9%
Prevalence
9%
Computer Assisted Tomography
9%
Metastatic Breast Cancer
9%
Tamoxifen
9%
Intensity Modulated Radiation Therapy
9%
Meta-Analysis
8%
Rectum Cancer
8%
Adjuvant Chemotherapy
8%
Placebo
8%
Peritoneum Metastasis
8%
Ovarian Cancer
8%
Radiation Oncology
8%
Survival Rate
8%
Proportional Hazards Model
8%
Epidermal Growth Factor Receptor
8%
Volumetric Modulated Arc Therapy
7%
Lymph Node
7%
Geriatric Assessment
7%
Cancer Treatment
7%
Hormone Therapy
7%
Odds Ratio
7%
Immune Checkpoint Inhibitor
7%
Tumor Cell
7%
Distant Metastasis
7%
Clinician
7%
Cancer
7%
P16
7%
Fluorouracil
7%
Fluorodeoxyglucose F 18
7%
Targeted Therapy
6%
Volume CT
6%
Contouring
6%
Randomized Clinical Trial
6%
Health Care
6%
Combination Therapy
6%
Adaptive Radiotherapy
6%
Frailty
6%
Monotherapy
6%
Cancer Radiotherapy
6%
Capecitabine
6%
Side Effect
6%
Cisplatin
6%
Lymph Node Metastasis
6%
Drug Megadose
6%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
70%
Overall Survival
59%
Chemotherapy
57%
Neoplasm
55%
Malignant Neoplasm
54%
Metastatic Colorectal Cancer
42%
Melanoma
27%
Progression Free Survival
26%
Disease
26%
Non Small Cell Lung Cancer
25%
Oxaliplatin
20%
Cohort Study
20%
Head and Neck Cancer
20%
Adverse Event
19%
Placebo
17%
Biological Marker
17%
Recurrent Disease
17%
Clinical Trial
16%
Comorbidity
15%
Cetuximab
15%
Lung Cancer
15%
Irinotecan
14%
Metastatic Melanoma
14%
Immunotherapy
13%
Metastatic Breast Cancer
13%
Fluorouracil
12%
Bevacizumab
12%
Colorectal Carcinoma
12%
Chemoradiation Therapy
12%
Cisplatin
11%
Pancreas Cancer
11%
Docetaxel
11%
Ovary Cancer
10%
Epidermal Growth Factor Receptor
10%
Estrogen Receptor
10%
Capecitabine
10%
Phase II Trials
9%
Polyethylene Terephthalate
9%
Prevalence
9%
Monotherapy
9%
Nausea and Vomiting
9%
Paclitaxel
9%
Ipilimumab
8%
Antiemetic Agent
8%
Squamous Cell Carcinoma
8%
Glioblastoma
8%
Primary Tumor
8%
Randomized Controlled Trial
7%
Prostate Cancer
7%
Survival Rate
7%
Tamoxifen
7%
Epirubicin
7%
Cyclophosphamide
7%
Combination Therapy
7%
Side Effect
7%
Nausea
7%
Head and Neck Squamous Cell Carcinoma
6%
Gemcitabine
6%
Immune Checkpoint Inhibitor
6%
Peritoneum Metastasis
6%
Nivolumab
6%
Metastasis
6%
Tolerability
5%
Chemotherapy Induced Nausea and Vomiting
5%
Solid Malignant Neoplasm
5%
Estrogen Receptor Positive Breast Cancer
5%
Carboplatin
5%
Brain Metastasis
5%
Recurrence Free Survival
5%
Thyroid Cancer
5%
Retrospective Study
5%
Nursing and Health Professions
Malignant Neoplasm
39%
Radiotherapy
28%
Disease
20%
Breast Cancer
18%
Quality of Life
15%
Health Care Personnel
11%
Practice Guideline
11%
Palliative Therapy
11%
Patient-Reported Outcome
9%
Confidence Interval
9%
Head and Neck Cancer
8%
Cancer Therapy
8%
Systematic Review
7%
Adverse Event
7%
Neoplasm
6%
Clinical Practice
6%
Overall Survival
6%
Frailty
6%
Metastatic Breast Cancer
5%
Cross-Sectional Study
5%
Cohort Analysis
5%
Positron Emission Tomography-Computed Tomography
5%
Prostate Cancer
5%
Metastatic Colorectal Cancer
5%